leisure time -WSS

leisure time

author：leisure time 2025-09-02 08:19:18 - browse：142

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： What to do when lifesaving products contribute to climate change

WSS

CRISPR pioneers react to Casgevy, first gene

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Ransomware attacks on hospitals: Study outlines patient impact

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Medicare details structure of new drug price negotiation program

David Sabatini, ex

FDA approval of Sarepta Duchenne genetic therapy gives me hope

PBM reforms clear House panel

The high cost of giving birth even with insurance

The EPA's new lead rule: How one expert crunched the numbers

Walensky prepares to leave CDC — and Congress — behind

What don’t we know about an Alzheimer’s drug side effect?

focus

What to do when lifesaving products contribute to climate change

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Flagship Pioneering launches a new biotech in two countries

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Wegovy, Zepbound and weight loss drugs that preserve muscle

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

hotspot

focus

Wikipedia

Wikipedia